Infectious Diseases in Critical Care Medicine

(ff) #1

  1. Dietze B, Rath A, Wendt C, et al. Survival of MRSA on sterile goods packaging. J Hosp Infect 2001;
    49(4):255–261.

  2. Embil J, McLeod J, Al-Barrak AM, et al. An outbreak of the methicillin-resistantStaphylococcus
    aureuson a burn unit: potential role of contaminated hydrotherapy equipment. Burn 2001;27(7):
    681–688.

  3. Rampling A, Wiseman S, Davis L, et al. Evidence that hospital hygiene is important in the control of
    methicillin resistantStaphylococcus aureus. J Hosp Infect 2001;49(2):109–116.

  4. Farr BM. Prevention and control of methicillin-resistantStaphylococcus aureusinfections. Curr Opin
    Infect Dis 2004;17(8):317–322.

  5. Arnold MS, Dempsey JM, Fishman M, et al. The best hospital practices for controlling methicillin-
    resistantStaphylococcus aureus: on the cutting edge. Infect Control Hosp Epidemiol 2002;23(2):69–76.

  6. Boyce JM. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect 2001;
    48(suppl A):S9–S14.

  7. Watanakunakorn C, Axelson C, Bota B, et al. Mupirocin ointment with and without chlorhexidine
    baths in the eradication ofStaphylococcus aureusnasal carriage in nursing home residents. Am J Infect
    Control 1995;23(5):306–309.

  8. Vivoni AM, Santos KRN, de-Oliveira MP, et al. Mupirocin for controlling methicillin-resistant
    Staphylococcus aureus: lessons from a decade of use at a university hospital. Infect Control Hosp
    Epidemiol 2005;26(7):662–667.

  9. Silvestri L, Milanese M, Oblach L, et al. Enteral vancomycin to control methicillin-resistantStaphylococcus
    aureusoutbreak in mechanically ventilated patients. Am J Infect Control 2002;30(7):391–399.

  10. Thorburn K, Taylor N, Saladi SM, et al. Use of surveillance cultures and enteral vancomycin to
    control methicillin-resistantStaphylococcus aureusin a paediatric intensive care unit. Clin Microbiol
    Infect 2006;12(1):35–42.

  11. Sandri AM, Dalarosa MG, de Alcaˆntara LR, et al. Reduction in incidence of nosocomial methicillin-
    resistantStaphylococcus aureus(MRSA) infection in an intensive care unit: role of treatment with
    mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Control Hosp
    Epidemiol 2006;27(2):185–187.

  12. Gould IM, MacKenzie FM, MacLennan G, et al. Topical antimicrobials in combination with
    admission screening and barrier precautions to control endemic methicillin-resistantStaphylococcus
    aureusin an intensive care unit. Int J Antimicrob Agents 2007;29(5):536–543.

  13. Regev-Yochay G, Rubinstein E, Barzilai A, et al. Methicillin-resistant Staphylococcus aureusin
    neonatal intensive care unit. Emerg Infect Dis 2005;11(3):453–456.

  14. Khoury J, Jones M, Grim A, et al. Eradication of methicillin-resistantStaphylococcus aureusfrom a
    neonatal intensive care unit by active surveillance and aggressive infection control measures. Infect
    Control Hosp Epidemiol 2005;26(7):616–621.

  15. Doebbeling BN, Breneman DL, Neu HC, et al. Elimination ofStaphylococcus aureusnasal carriage in
    healthcare workers: analysis of six clinical trials with calcium mupirocin ointment. Clin Infect Dis
    1993;17(9):466–474.

  16. Reagan DR, Doebbeling BN, Pfaller MA, et al. Elimination of coincidentStaphylococcus aureusnasal
    and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med
    1991;114(2):101–106.

  17. Chenoweth CE. Enterococcus species. In: Mayhall CG, ed. Hospital Epidemiology and Infection
    Control. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004:529–544.

  18. Bugg TDH, Dutka-Malen S, Arthur M, et al. Identification of vancomycin resistance protein VanA as
    a D-Alanine: D-Alanine ligase of altered substrate specificity. Biochemistry 1991;30(8):2017–2021.

  19. Willems RJL, Homan W, Top J, et al. Variantespgene as a marker of a distinct genetic lineage of
    vancomycin-resistantEnterococcus faeciumspreading in hospitals. Lancet 2001;357(9259):853–855.

  20. Rice LB, Carias L, Rudin S, et al. A potential virulence gene,hylEfm, predominates inEnterococcus
    faeciumof clinical origin. J Infect Dis 2003;187(3):508–512.

  21. Shay DK, Maloney SA, Monetcalvo M, et al. Epidemiology and mortality risk of vancomycin-
    resistant enterococcal bloodstream infections. J Infect Dis 1995;172(10):993–1000.

  22. Montecalvo MA, Shay DK, Patel P, et al. Bloodstream infections with vancomycin-resistant
    enterococci. Arch Intern Med 1996;156(13):1458–1462.

  23. Stroud L, Edwards J, Danzig l, et al. Risk factors for mortality associated with enterococcal
    bloodstream infections. Infect Control Hosp Epidemiol 1996;17(9):576–580.

  24. Edmond MB, Ober JF, Dawson JD, et al. Vancomycin-resistant enterococcal bacteremia: natural
    history and attributable mortality. Clin Infect Dis 1996;23(12):1234–1239.

  25. Stosor V, Peterson LR, Postelnick M, et al.Enterococcus faeciumbacteremia. Does vancomycin
    resistance make a difference? Arch Intern Med 1998;158(5):522–527.


124 Mayhall

Free download pdf